April 1, 2026
CEO Spyros Papapetropoulos shares insights on CNS drug development's future, purpose-driven leadership, and building high-performing biotech teams.
March 31, 2026
Novogaia's CEO Tess Bevers discusses using AI and mass spectrometry to unlock the vast, untapped potential of fungi for novel drug discovery.
March 30, 2026
Aphaia Pharma's co-founder discusses a novel drug that reactivates the gut's hormone system to treat obesity, aiming for global access.
March 25, 2026
EG427 CEO Philippe Chambon discusses his journey from VC to operator, pioneering pinpoint DNA medicine for neurological diseases in Europe.
March 19, 2026
Medera Biopharmaceuticals is pioneering cardiac gene therapy with a human mini-heart platform and a 100x lower-dose intracoronary delivery.
March 18, 2026
Cellares CEO Fabian Gerlinghaus on industrializing cell therapy with a fully automated platform, slashing costs & scaling to meet global demand.
March 11, 2026
Formation Bio's VP of Talent, Emily Gransky, on leveraging proprietary AI to scale an AI-native drug development company through value-based hiring.
March 10, 2026
Rejuvenate Biomed CEO Ann Belien on tackling aging with combination therapies, targeting sarcopenia, and building a biotech in Belgium.
March 9, 2026
Santhera CFO Catherine Isted on her unique career path, biotech financing, leadership lessons, and advice for women in the industry.
February 19, 2026
Arcus Biosciences CEO Terry Rosen on building a discovery-first biotech, its differentiated pipeline, and its plan to win in oncology.
February 16, 2026
Memo Therapeutics CEO Erik van den Berg on tackling BK virus in transplant patients with a potent antibody, impressive Phase 2 data, & platform tech.
February 12, 2026
Biotech leader Declan Doogan shares his journey from big pharma to startups & Causeway's groundbreaking microRNA treatment for tendon disease.
February 11, 2026
Rectify Pharma CEO Raj Devraj on the art of drug hunting, de-risking breakthrough science, strategic team building, and navigating fundraising.
February 3, 2026
Enara Bio CEO Kevin Pojasek on pioneering 'dark antigen' cancer targets, building a people-first culture, and the next frontier for solid tumors.
January 22, 2026
Delpha Therapeutics CEO Kevin Marks discusses 'activation lethality,' a novel cancer therapy, the scientist-to-CEO journey, and building a culture-first biotech.
January 15, 2026
AeroRx CEO Ahmet Tutuncu discusses a $21M Series A for a novel nebulized dual bronchodilator targeting severe COPD patients unable to use inhalers.
January 5, 2026
Resolution Therapeutics CEO Amir Hefni discusses a novel macrophage cell therapy for liver disease, now in a Phase 1/2 trial with data due in 2026.
December 19, 2025
BridgeBio executive Justin To on pioneering genetic disease treatments with a decentralized R&D model, turning academic science into patient impact.
SpliceBio CEO Miquel Vila-Perello discusses their protein splicing platform, tackling Stargardt disease, and navigating biotech fundraising.
December 16, 2025
Beacon Therapeutics CEO Lance Baldo on advancing a Phase 3 gene therapy for blindness, the advantages of ocular treatments, and global leadership.
December 15, 2025
Luba Greenwood, CEO of Gallop Oncology, discusses biotech leadership, disciplined fundraising, and the essential CEO skills for today's market.
December 9, 2025
CDR Life CEO Christian Leisner shares insights on building a biotech, pioneering T-cell engagers, and leveraging Switzerland's unique ecosystem.
